Oksn-191 |verified| ★ Must See

| Phase | Sponsor | Indication | Status (as of Apr 2026) | |-------|---------|------------|------------------------| | | Oksen Therapeutics | Type‑2 Diabetes with MCI (T2DM‑MCI) | IND filing planned Q4 2026 | | Phase I | Oksen Therapeutics (planned) | Safety, PK, and PD in healthy volunteers | Dose‑escalation (single ascending dose 5–150 mg) | | Phase Ib/IIa | Oksen Therapeutics (planned) | Proof‑of‑concept in T2DM‑MCI patients (n ≈ 60) | Primary endpoints: change in HbA1c, ADAS‑Cog13 at 12 weeks | | Phase IIb (partner‑led) | NeuroMetrix Inc. | Early AD (prodromal) | Candidate for combination with anti‑amyloid antibody |

While the semiconductor narrative is the strongest, the limited data also leaves room for other interpretations: oksn-191

Based on the typical nomenclature used by this company and similar entities, 🎙️ Likely Identity: Audio Equipment | Phase | Sponsor | Indication | Status

(e.g., "I found a microphone labeled OKSN-191.") 🎙️ Likely Identity: Audio Equipment (e.g.